CRISPR Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
ZUG, Switzerland and BOSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 10:30 a.m. ET.
A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.
About CRISPR TherapeuticsSince its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.
Investor Contact:+1-617-307-7503ir@crisprtx.com
Media Contact:+1-617-315-4493media@crisprtx.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Jim Cramer on EHang (EH): 'I'm Not Going to Really Want to Do a Lot of China Right Now'
We recently published a list of . In this article, we are going to take a look at where EHang Holdings Limited (NASDAQ:EH) stands against other stocks that Jim Cramer discusses. A caller asked for Cramer's opinion on EHang Holdings Limited (NASDAQ:EH), and he said: 'You know, I'm not going to really want to do a lot of China right now. I think that the President and China, just don't feel that, I just don't, I'm not getting that vibe, you know what I mean?' EHang (NASDAQ:EH) develops and sells autonomous aerial vehicles and related systems for use in passenger transport, logistics, urban management, and aerial media. The company offers aircraft models, flight control technology, operational software, vertiports, and charging infrastructure for electric vertical takeoff and landing operations. A modern commercial jet airliner decorated with the company logo in flight against a clear blue sky. On May 27, BofA reduced the price target on EHang (NASDAQ:EH) from $26 to $24 and maintained a Buy rating after the company missed expectations in the first quarter due to weaker sales. Taking the first-quarter performance into account, the firm lowered its volume sales projections for 2025 and 2026 by 7% and 8%, and revised its non-GAAP net profit estimates for those years down by 63% and 12%, respectively. Overall, EH ranks 11th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of EH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Post
an hour ago
- New York Post
New Manhattan homes for menswear stores Charles Tyrwhitt, Tom Ford
London-based menswear store Charles Tyrwhitt is moving from 437 Madison Ave. to RFR Realty's 477 Madison, doubling its space in the process. Tyrwhitt signed for 3,800 square at the East 51st Street corner. The deal was handled for the landlord by MONA, a retail brokerage backed by RFR's Aby Rosen. Cushman & Wakefield acted for the tenant. Charles Tywhitt has a half-dozen Manhattan locations. Advertisement The building's offices are mostly leased. Recent signings include for Treville Capital and Fiera Capital. 477 Madison Ave. will be the new home menswear store Charles Tyrwhitt. One more Park Avenue office address has filled up. Advertisement Tom Ford Fashion signed a 10-year, 11,118 square-foot lease at SL Green's 500 Park Ave., bringing the landmarked, 201,000 square-foot building at East 59th Street to 100% leased. Tom Ford Fashion has signed a 10-year lease for 500 Park Ave., above. Brian Zak/NY Post Advertisement Other office tenants include The Georgetown Company, Vera Wang and Friedland Properties. Furniture store FRATO's flagship showroom is the retail tenant. Meanwhile, the former Hammacher Schlemmer headquarters building at 145 E. 57th St. can also boast 100% occupancy. Data Science Innovators took 5,067 square feet, landlord ABS Partners announced. Danish furniture maker Carl Hansen & Son replaced Hammacher Schlemmer on the retail floors.
Business Insider
2 hours ago
- Business Insider
The Week That Was, The Week Ahead: Macro & Markets, June 8, 2025
Everything to Know about Macro and Markets Stocks clocked in large weekly gains, returning to positive territory year-to-date. The Dow Jones Industrial Average (DJIA) rose by 1.17%, the S&P 500 (SPX) increased by 1.50%, and the tech-heavy Nasdaq-100 (NDX) gained 1.97% for the week. The S&P 500 finished more than 20% above April's low, reclaiming the 6,000 mark first reached in February, although it remained about 2% shy of its record high. Confident Investing Starts Here: Macro Steers the Markets The week began on a positive note, losing some steam in the second half. The weakness in PMI reports – with the manufacturing activity contracting for a third month in a row and services activity shrinking for the first time in 11 months – infused some gloom. However, Friday saw stocks find their footing again on solid job gains, which allayed fears about an imminent economic downturn. U.S. jobs growth stayed strong in May, climbing 139,000 with unemployment unchanged at 4.2%. Although the March and April reports were revised downward, May's report reassured investors, as it reflected a very gradual cooling of the labor market. Still, diving into the job report's details, a stronger-than-expected wage growth continues to put a floor under inflation. This supports the Federal Reserve's 'wait and see' stance, despite President Trump's demands for a cut. According to the CME FedWatch Tool, the chances of a June cut are nil, and July's rate decrease looks increasingly improbable. Prices in interest rate futures markets imply that investors expect two quarter-point rate cuts by year-end, with the first cut not expected until September. Wrapping Up the Season Despite tariff headwinds and macro volatility, S&P 500 companies delivered solid results last quarter. Index members reported 12.9% year-over-year earnings growth – the second straight double-digit increase. 78% of firms – above the five-year average – exceeded EPS estimates. However, the number of companies issuing negative EPS guidance (68) was also above the average. In Q1, the Healthcare sector reported the highest earnings growth, 43%, leaving the Magnificent Seven cohort's 27.7% increase in the dust. In fact, Mag 7's earnings growth rate was below the average (32.1%) of the previous three quarters. Still, three members of the Magnificent bunch – Alphabet (GOOGL), Amazon (AMZN), and Nvidia (NVDA) – are among the top five contributors to earnings growth for the S&P 500 for the first quarter. Interestingly, Bristol Myers Squibb (BMY) and Gilead Sciences (GILD) were the other top contributors. Stocks That Made the News ▣ Tesla (TSLA) lost nearly 15% over the week following the ugly social media spat between Elon Musk and President Donald Trump. The feud flared up over the impending budget bill, with Musk calling it 'disgusting', and followed by Trump's threat to take away billions of dollars in government subsidies and contracts awarded to Musk's businesses. Although shares rebounded on Friday as Musk and Trump moved to cool tensions, the spat cost Tesla over $150 billion loss in market cap. ▣ Broadcom (AVGO) fell on Friday, wiping out its weekly gain, after the chip giant only narrowly surpassed analyst revenue and expectations. In addition, its current quarter revenue guidance was also just above consensus. Solid, but not a blowout quarter and outlook, weighed on shares that recently hit all-time highs. Still, the company delivered on the AI narrative, reporting surging demand and upping AI networking revenue guidance. ▣ Microsoft (MSFT) continued its climb, hitting a fresh record on Friday as analysts raised price targets on acceleration in Azure and AI-related revenue growth. According to Goldman Sachs, Microsoft's cloud revenue could more than double by 2029. The tech leader's market cap has reached $3.5 trillion, surpassing that of Nvidia (NVDA) and making MSFT the largest company in the world. ▣ Lululemon (LULU) shares dove by 20% on Friday, capping large weekly losses, despite earnings beat. The apparel retailer cut guidance on macroeconomic uncertainty and the impact of tariffs that might force LULU to increase prices. ▣ DocuSign (DOCU) was another notable decliner, sinking nearly 19% post earnings. The company reported a strong financial performance, but a miss on billings raised investor fears about future growth. The Q1 2025 earnings season is practically over, but several notable earnings releases are still scheduled for the next few days. These include Casey's General (CASY), Oracle (ORCL), Chewy (CHWY), and Adobe (ADBE).
